LitCovid-sample-Enju  

PMC:7205724 / 127-413 JSONTXT 13 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T18 3-4 -COMMA- denotes ,
T19 5-20 NNS denotes immunoglobulins
T20 20-21 -COMMA- denotes ,
T21 22-25 CC denotes and
T22 26-41 NNS denotes corticosteroids
T23 43-53 NNS denotes Highlights
T24 54-55 IN denotes •
T25 57-61 NNP denotes IVIG
T26 61-62 -COMMA- denotes ,
T27 63-71 VBN denotes combined
T28 72-76 IN denotes with
T29 77-90 NN denotes moderate-dose
T30 91-93 IN denotes of
T31 94-109 NNS denotes corticosteroids
T32 109-110 -COMMA- denotes ,
T33 111-116 MD denotes might
T34 117-124 VB denotes improve
T35 125-132 NN denotes patient
T36 133-141 NNS denotes outcomes
T37 143-144 PDT denotes •
T38 146-149 DT denotes The
T39 150-153 NN denotes use
T40 154-156 IN denotes of
T41 157-172 NNS denotes corticosteroids
T42 173-178 MD denotes might
T43 179-189 VB denotes accelerate
T44 190-198 NN denotes recovery
T45 199-203 IN denotes from
T46 204-212 NN denotes COVID-19
T47 214-215 PDT denotes •
T48 217-219 DT denotes No
T49 220-230 VBN denotes controlled
T50 231-239 JJ denotes clinical
T51 240-246 NNS denotes trials
T52 247-252 VBP denotes exist
T53 253-255 IN denotes on
T54 256-259 DT denotes the
T55 260-263 NN denotes use
T56 264-266 IN denotes of
T57 267-282 NNS denotes corticosteroids
T58 283-286 IN denotes for
R16 T19 T18 arg2Of immunoglobulins,","
R17 T21 T20 arg1Of and,","
R18 T18 T21 arg1Of ",",and
R19 T22 T21 arg2Of corticosteroids,and
R20 T25 T24 arg1Of IVIG,•
R21 T25 T26 arg1Of IVIG,","
R22 T25 T27 arg2Of IVIG,combined
R23 T27 T28 arg1Of combined,with
R24 T29 T28 arg2Of moderate-dose,with
R25 T29 T30 arg1Of moderate-dose,of
R26 T31 T30 arg2Of corticosteroids,of
R27 T34 T32 arg1Of improve,","
R28 T25 T33 arg1Of IVIG,might
R29 T34 T33 arg2Of improve,might
R30 T25 T34 arg1Of IVIG,improve
R31 T36 T34 arg2Of outcomes,improve
R32 T36 T35 arg1Of outcomes,patient
R33 T39 T37 arg1Of use,•
R34 T39 T38 arg1Of use,The
R35 T39 T40 arg1Of use,of
R36 T41 T40 arg2Of corticosteroids,of
R37 T39 T42 arg1Of use,might
R38 T43 T42 arg2Of accelerate,might
R39 T39 T43 arg1Of use,accelerate
R40 T44 T43 arg2Of recovery,accelerate
R41 T44 T45 arg1Of recovery,from
R42 T46 T45 arg2Of COVID-19,from
R43 T51 T47 arg1Of trials,•
R44 T51 T48 arg1Of trials,No
R45 T51 T49 arg2Of trials,controlled
R46 T51 T50 arg1Of trials,clinical
R47 T51 T52 arg1Of trials,exist
R48 T52 T53 arg1Of exist,on
R49 T55 T53 arg2Of use,on
R50 T55 T54 arg1Of use,the
R51 T55 T56 arg1Of use,of
R52 T57 T56 arg2Of corticosteroids,of
R53 T55 T58 arg1Of use,for